Prediction of residual time to AIDS and death based on markers and cofactors

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 514-521

  Geskus, Ronald B ^a,e   Miedema, Frank A ^b   Goudsmit, Jaap ^d   Reiss, Peter ^c   Schuitemaker, Hanneke ^b   Coutinho, Roel A ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CRUCELL HOLLAND BV   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AIDS progression; Baseline model; Markers; Predictive value; Prognosis; Therapy guidelines

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE MARKER; GENETIC ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYSICIAN ATTITUDE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN PROTEIN INTERACTION; SEROPREVALENCE; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0345269688     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00008     Document Type: Article

References (43)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on clinical practices for treatment of HIV infection, 2001. Available at: http://www.hivatis.org/. Accessed March 15, 2002.
2. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel, JAMA 2000;283:381-90.
3. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
4. + T-cell count and function: markers with reciprocal predictive value over time since seroconversion. AIDS 1997;11:1799-806.
5. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998;12:1639-43.
6. Sabin CA, Devereux H, Phillips AN, et al. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998;12:1347-52.
7. Altman DG, Royston P. What do we mean by validating a prognostic model. Stat Med 2000;19:453-73.
8. Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000;56:249-55.
9. van Griensven GJP, Tielman RAP, Goudsmit J, et al. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987;125:1048-57.
10. Geskus RB. Methods for estimating the AIDS incubation time distribution when date of seroconversion is censored. Stat Med 2001;20:795-812.
11. Geskus RB. On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion. Stat Med 2000;19:1753-69.
12. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
13. Collaborative Group on AIDS Incubation and HIV Survival Including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative re-analysis, Lancet 2000;355:1131-7.
14. Meyer L, Magierowska M, Hubert JB, et al. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. AIDS 1999;13:624-6.
15. Ioannidis JPA, Rosenber PS, Goedert JJ, et al. Effects of CCR5-δ32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-95.
16. De Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-90,
17. van Rij RP, De Roda Husman AM, Brouwer M, et al. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998;178: 1806-11.
18. Spijkerman IJB, Koot M, Prins M, et al. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995;9: 1085-92.
19. Koot M, Vos AHV, Keet IPM, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
20. Björndal Å, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biologic phenotype. J Virol 1997;71:7478-87.
21. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
22. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer-Verlag, 2000.
23. Ancelle-Park RA. European AIDS definition. Lancet 1992;339: 671.
24. Korn EL, Simon R. Measures of explained variation for survival data. Stat Med 1990;9:487-503.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
26. Harrell FE, Jr. Regression modeling strategies. Springer-Verlag, 2001.
27. S-PLUS 2000 guide to statistics. Vol. 2. Seattle: Mathsoft, Data Analysis Products Division, 1999.
28. Harrell FE. Design: S functions for biostatistical/epidemiologic modeling, testing, estimation, validation, graphics, and prediction. 1999. Programs available at: http://hesweb1.med.virginia.edu/biostat/s/index.html (Divisions/Biostatistics and Epidemiology/Statistical Computing Tools) or http://lib.stat.cmu.edu/. Accessed March 15, 2002.
29. Shi M, Taylor JMG, Currier RJ et al. Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:309-16.
30. Henderson R, Jones M, Stare J. Accuracy of point predictions in survival analysis. Stat Med 2001;20:3083-96.
31. Berzuini C, Larizza C. A unified approach for modeling longitudinal and failure time data, with application in medical monitoring. IEEE Transactions on Pattern Analysis and Machine Intelligence 1996;18:109-23.
32. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. Stat Med 1996;15:1663-85.
33. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics 1997;53:330-9.
34. Touloumi G, Pocock SJ, Babiker AG, et al. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. Stat Med 1999;18:1215-33.
35. Xu J, Zeger SL. Joint analysis of longitudinal data comprising repeated measures and times to events. Appl Stat 2001;50:375-87.
36. Segal MR, James IR, French MAH, et al. Statistical issues in the evaluation of markers of HIV progression. Int Stat Rev 1995;63: 179-97.
37. Phillips AN, Sabin CA, Elford J, et al. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. Am J Epidemiol 1993;138:870-8.
38. Phillips AN, Pezzotti P, Lepri AC, et al. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994;8:1299-305.
39. Shi M, Taylor JMG, Muñoz A. Models for residual time to AIDS. Lifetime Data Anal 1996;2:31-49.
40. Hoover DR, Muñoz A, He Y, et al. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population. Stat Med 1994;13:2127-39.
41. Hoover DR. The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease: a review of the literature. Drugs 1995;49:20-36.
42. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
43. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate and late stages of HIV infection. JAMA 1996;275:1329-1334.